Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas.

@article{Henze2005CharacterizationO6,
  title={Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas.},
  author={Marcus Henze and Antonia Dimitrakopoulou-Strauss and Stefanie Milker-Zabel and Jochen Schuhmacher and Ludwig G. Strauss and Josef Doll and Helmut R. Maecke and Michael Eisenhut and J{\"u}rgen Debus and Uwe Haberkorn},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={2005},
  volume={46 5},
  pages={763-9}
}
UNLABELLED Because biopsy has a high risk of hemorrhage and the findings of CT and MRI are often ambiguous, especially at the base of the skull, additional methods for the characterization of intracranial tumors are needed. Meningiomas show high expression of the somatostatin receptor subtype 2 and thus offer the possibility of receptor-targeted imaging. We used the somatostatin analog (68)Ga-DOTA-d-Phe(1)-Tyr(3)-octreotide (DOTA-TOC) labeled with the positron emitter (68)Ga (half-life, 68 min… CONTINUE READING